NCT06718270View on ClinicalTrials.gov

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

January 3, 2027

Study Completion Date

December 31, 2027

Conditions
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
Interventions
DRUG

CAR-T cells Infusion

chimeric antigen receptor T cells

Trial Locations (1)

200000

RECRUITING

Shanghai Changzheng Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Shanghai Changzheng Hospital

OTHER